Clinical Trial Update: Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating co-administered HGP0904, HGP0608, and HGP0816 in hypertension and hyperlipidemia has completed. The entry notes the status as COMPLETED…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Hypertension

Drugs mentioned

• HGP0608
• HGP0816
• HGP0904

Snippet

Sponsor: Hanmi Pharmaceutical Company Limited | Conditions: Hypertension, Hyperlipidemia | Phase 3 | Status: COMPLETED